LIFECORE BIOMEDICAL, INC. DE
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Lifecore Biomedical, Inc. De
Pharmaceutical Preparations, SIC 2834
Lifecore Biomedical, Inc. is a contract development and manufacturing organization that specializes in the development, manufacturing, and aseptic filling of sterile injectable pharmaceutical drugs and medical devices. The company manufactures pharmaceutical-grade hyaluronic acid through bacterial fermentation in both bulk and filled formats such as syringes, vials, and cartridges, alongside non-hyaluronic acid formulations. Its service offerings include formulation development, analytical method validation, process scale-up, stability testing, and clinical trial material production. Lifecore manages its operations through a single integrated business segment. The company serves emerging and global biopharmaceutical and biotechnology firms, as well as academic and commercial research organizations.
The company is headquartered in Chaska, Minnesota, where it operates three manufacturing facilities encompassing a total of 250,000 square feet within a two-mile radius. Lifecore employs 406 full-time workers, all based in the United States. Its production sites maintain regulatory clearances and certifications from authorities in the United States, Europe, Japan, and Brazil.
Summary of the business section of Lifecore Biomedical, Inc. De's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LIFECORE BIOMEDICAL, INC. DE
- Founded
- 2007
- Headquarters
- Chaska, MN
- Address
- 3515 Lyman Boulevard 55318
- Phone
- (952) 368-4300
- Website
- lifecore.com
- Employees
- 382, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- May 25
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- LFCR
- Exchange
- Nasdaq
- IPO date
- Feb 15, 1996
- Shares outstanding
- 38M, Jul 29, 2026
- Public float
- $222.97M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- SEC CIK
- 1005286
- CUSIP
- 514766104
- ISIN
- US5147661046
- LEI
- 549300EHBZ5OM9ND9O43
- EIN
- 94-3025618
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Josephs | Chief Executive Officer, Director | 592,915 |
| Thomas D. Salus | Chief Legal & Administration | 246,333 |
| Ryan David Lake | Chief Financial Officer | 336,691 |
| Legion Partners, L.P. II | Director | 2,968,409 |
| Raymond T. White | Director | – |
| Legion Partners, L.P. I | Director | 4,507,236 |
| Legion Partners Holdings, LLC | Director | 4,481,329 |
| Legion Partners, LLC | Director | 2,940,340 |
| Christopher S. Kiper | Director | 2,998,409 |
| Legion Partners Asset Management, LLC | Director | 4,461,823 |
| Lovas Katrina Houde | Director | 135,319 |
| Nelson Obus | Director | 2,319,794 |
| Joshua Schechter | Director | 135,080 |
| Matthew E. Korenberg | Director | 69,967 |
| Jason Aryeh | Director | 69,967 |
| Paul Harold Johnson | Director | 69,967 |
| Humberto Calheiros Antunes | Director | 72,967 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Paul Josephs | $545.64K | $2.42M | $395.24K | $68 | $118 |
| FY2024 James GHall | $2.49M | $1.69M | $1.29M | $47 | $93 |
| FY2024 Paul Josephs | $10.25M | $11.52M | $1.29M | $47 | $93 |
| FY2023 Albert Bolles | $1.34M | $640.59K | $927.10K | $66 | $79 |
| FY2023 James GHall | $1.76M | $1.40M | $927.10K | $66 | $79 |
| FY2022 Albert Bolles | $956.81K | $711.50K | $687.61K | $82 | $82 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had 382 full-time employees, of whom 177 were dedicated to manufacturing, 93 to quality and regulatory affairs, 78 to general operations, and 34 to sales, marketing and administrative activities.”
Corporate history
Events identified from SEC filings